Martin Lagging

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. ncbi request reprint Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Guldhedsgatan 10B, S 413 46 Goteborg, Sweden
    J Infect Dis 185:1165-9. 2002
  2. doi request reprint Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Martin Lagging
    Department of Infectious Diseases Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Scand J Gastroenterol 48:839-47. 2013
  3. doi request reprint Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations
    Martin Lagging
    Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Goteborg, Sweden
    Scand J Infect Dis 44:502-21. 2012
  4. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
  5. doi request reprint Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
    Martin Lagging
    Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
    Hepatology 47:1837-45. 2008
  6. pmc Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
    Martin Lagging
    Department of Infectious Diseases Virology, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 6:e17232. 2011
  7. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
  8. doi request reprint Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations
    Martin Lagging
    Department of Infectious Diseases and Virology, Sahlgrenska University Hospital, Goteborg
    Scand J Infect Dis 41:389-402. 2009
  9. pmc Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden
    J Clin Microbiol 40:4224-9. 2002
  10. ncbi request reprint Nosocomial transmission of HCV in a cardiology ward during the window phase of infection: an epidemiological and molecular investigation
    L Martin Lagging
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Infect Dis 34:580-2. 2002

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Guldhedsgatan 10B, S 413 46 Goteborg, Sweden
    J Infect Dis 185:1165-9. 2002
    ....
  2. doi request reprint Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Martin Lagging
    Department of Infectious Diseases Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Scand J Gastroenterol 48:839-47. 2013
    ..Uncertainty remains regarding the efficacy of retreatment with current standard-of-care peg-interferon (peg-IFN) and ribavirin among patients infected with hepatitis C virus (HCV) genotypes 2 or 3 with relapse after prior therapy...
  3. doi request reprint Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations
    Martin Lagging
    Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Goteborg, Sweden
    Scand J Infect Dis 44:502-21. 2012
    ..e. HCV RNA below 1000 IU/ml on day 7), or favourable baseline characteristics and undetectable HCV RNA week 4, treatment can be shortened to 12-16 weeks, provided that no dose reductions are needed...
  4. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
    ..HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study)...
  5. doi request reprint Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
    Martin Lagging
    Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
    Hepatology 47:1837-45. 2008
    ..If neither of these two criteria were met for patients > or = 40 years old, 24 weeks of therapy was superior (P < 0.0001)...
  6. pmc Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
    Martin Lagging
    Department of Infectious Diseases Virology, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 6:e17232. 2011
    ..Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients...
  7. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  8. doi request reprint Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations
    Martin Lagging
    Department of Infectious Diseases and Virology, Sahlgrenska University Hospital, Goteborg
    Scand J Infect Dis 41:389-402. 2009
    ..For liver transplant patients pre-emptive therapy is not recommended; hence, treatment should be deferred until histological recurrence...
  9. pmc Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden
    J Clin Microbiol 40:4224-9. 2002
    ..0 years) and 4.41 for the sera obtained at the time of the second biopsy (median storage time, 6.6 years) compared to 5.96, the median for 102 different routine clinical patient samples...
  10. ncbi request reprint Nosocomial transmission of HCV in a cardiology ward during the window phase of infection: an epidemiological and molecular investigation
    L Martin Lagging
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Infect Dis 34:580-2. 2002
    ..It may, therefore, be prudent to restrict the use of such vials, in addition to promoting vigorous adherence to standard hygiene procedures in order to prevent the recurrence of similar outbreaks in the future...
  11. ncbi request reprint Progression of fibrosis in untreated patients with hepatitis C virus infection
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden, Department of Infectious Diseases, Goteborg University, Sweden
    Liver 22:136-44. 2002
    ....
  12. doi request reprint Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
    Asa Alsiö
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    Clin Infect Dis 50:e22-5. 2010
    ..Suboptimal drug concentrations may thus contribute to lack of response to therapy in patients with infection due to HCV genotype 2/3...
  13. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  14. doi request reprint Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
    Galia Askarieh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    Hepatology 51:1523-30. 2010
    ..006). In contrast, pretreatment levels of IP-10 in liver or in plasma did not affect the decline of HCV RNA between days 8 and 29, i.e., the second-phase decline, or later time points in any of these cohorts...
  15. pmc Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3
    Asa Alsiö
    Department of Infectious Diseases Virology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 7:e37521. 2012
    ....
  16. pmc Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3
    Karolina Rembeck
    Department of Infectious Diseases Virology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 7:e29370. 2012
    ....
  17. pmc Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
    Erik Alestig
    Department of Infection and Virology, University of Gothenburg, Gothenburg, Sweden
    BMC Infect Dis 11:124. 2011
    ..In the present study, the impact of these mutations on response kinetics and treatment outcome was explored in Caucasian patients...
  18. doi request reprint Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus
    Magnus Lindh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    J Infect Dis 203:1748-52. 2011
    ..The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment...
  19. pmc Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection
    Magnus Lindh
    Department of Infection and Virology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    J Clin Microbiol 45:2439-45. 2007
    ..On the basis of these findings, we propose a model of tailored treatment which takes into account the second-phase slope and the amount of HCV RNA after 21 days of treatment...
  20. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
    ....
  21. pmc PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
    Karolina Rembeck
    Department of Infectious Diseases Virology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    BMC Med Genet 13:82. 2012
    ..To evaluate the impact of PNPLA3 I148M variant on metabolic traits and treatment response in HCV genotype 2 and 3 infected patients...
  22. pmc Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection
    Jonas Soderholm
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 8:e56991. 2013
    ..The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells...
  23. ncbi request reprint Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers
    Sara Islam
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 40:867-72. 2005
    ..Being an invasive procedure, the liver biopsy is associated with complications, and a non-invasive alternative would be preferable...
  24. doi request reprint Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden
    Magdalena Ydreborg
    Department of Infectious Diseases and Clinical Virology, University of Gothenburg, Gothenburg, Sweden
    Scand J Infect Dis 43:522-7. 2011
    ..Following the discovery of the hepatitis C virus (HCV) in 1989, screening of all blood donors for antibodies became mandatory in Sweden as of 1 January 1992...
  25. ncbi request reprint Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients
    Johan Westin
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg University, SE 416 85 Goteborg, Sweden
    J Hepatol 37:837-42. 2002
    ..Its influence on disease progression is only partially understood. The aim of this study was to evaluate the impact of steatosis on fibrosis progression over time in relation to HCV genotype...
  26. pmc Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection
    Magdalena Ydreborg
    Department of Infectious Diseases Virology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 8:e80172. 2013
    ..The present study aimed to evaluate the impact of IL28B SNP variability on liver stiffness as accessed by transient elastography...
  27. doi request reprint Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience
    Magdalena Ydreborg
    Department of Infectious Diseases Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden
    Scand J Gastroenterol 47:710-7. 2012
    ....
  28. ncbi request reprint Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors
    Stefania Cavazza
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden
    Scand J Infect Dis 37:488-92. 2005
    ..Thus, having an indeterminate RIBA-3, including singular reactivity against NS5, may be associated with the presence of detectable levels of HCV RNA in clinical patients but not necessarily in blood donors...
  29. doi request reprint Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden
    Jesper Waldenström
    From the Department of Infectious Diseases Virology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
    Scand J Infect Dis 45:796-9. 2013
    ..Of 5.24 million Swedish plasma samples from December 1998 to September 2012, 5 additional window-phase donations were identified...
  30. pmc Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein
    Keith Meyer
    Department of Internal Medicine, Saint Louis University, 3635 Vista Ave, St Louis, Missouri 63110, USA
    J Virol 76:2150-8. 2002
    ....